{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T04:04:31Z","timestamp":1772424271911,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ad.2019.01.011","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T07:52:52Z","timestamp":1555660372000},"page":"448-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Manejo cl\u00ednico de los eventos adversos cut\u00e1neos en pacientes tratados con quimioterapia: consenso nacional de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda y de la Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica"],"prefix":"10.1016","volume":"110","author":[{"given":"O.","family":"Sanmart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Beato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Jin","family":"Suh-Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Espa\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Majem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"G\u00farpide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gr\u00e1valos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2019.01.011_bib0390","first-page":"e1","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: Part I. Conventional chemotherapeutic drugs","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0395","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","article-title":"Mucocutaneous reactions to chemotherapy","volume":"40","author":"Susser","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0400","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1385\/CRIAI:24:3:253","article-title":"Hypersensitivity reactions to chemotherapeutic drugs","volume":"24","author":"Shepherd","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ad.2019.01.011_bib0405","series-title":"Cancer, principles & practice of oncology","first-page":"375","article-title":"Alkylating agents","author":"Tew","year":"2011"},{"key":"10.1016\/j.ad.2019.01.011_bib0410","series-title":"Cancer, principles & practice of oncology","first-page":"386","article-title":"Platinum analogs","author":"Reed","year":"2011"},{"key":"10.1016\/j.ad.2019.01.011_bib0415","series-title":"Cancer, principles & practice of oncology","first-page":"393","article-title":"Antimetabolites","author":"Wasif Saif","year":"2011"},{"key":"10.1016\/j.ad.2019.01.011_bib0420","series-title":"Cancer, principles & practice of oncology","first-page":"402","article-title":"Topoisomerase-interacting agents","author":"Rasheed","year":"2011"},{"key":"10.1016\/j.ad.2019.01.011_bib0425","series-title":"Cancer, principles & practice of oncology","first-page":"413","article-title":"Antimicrotubule agents","author":"Abu-Khalaf","year":"2011"},{"key":"10.1016\/j.ad.2019.01.011_bib0430","series-title":"Physician's cancer chemotherapy drug manual.","first-page":"5","article-title":"Chemotherapeutic and biologic drugs","author":"Chu","year":"2012"},{"key":"10.1016\/j.ad.2019.01.011_bib0435","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2019.01.011_bib0440","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.ad.2019.01.011_bib0445","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.iac.2017.06.003","article-title":"Platinum chemotherapy hypersensitivity: Prevalence and management","volume":"37","author":"Otani","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.ad.2019.01.011_bib0450","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/10428194.2016.1213826","article-title":"Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia","volume":"58","author":"Burke","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ad.2019.01.011_bib0455","first-page":"387","article-title":"Doxorubicin-associated flare reactions","volume":"17","author":"Curran","year":"1990","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.ad.2019.01.011_bib0460","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0465","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7150\/jca.12986","article-title":"Evolving evidence of the efficacy and safety of nab-paclitaxel in the treatment of cancers with squamous histologies","volume":"7","author":"Loong","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.ad.2019.01.011_bib0470","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/10428190009054886","article-title":"Vasculitis and leukemia","volume":"40","author":"Paydas","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ad.2019.01.011_bib0475","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0536.1991.tb01699.x","article-title":"Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C","volume":"24","author":"De Groot","year":"1991","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2019.01.011_bib0480","series-title":"Dermatolog\u00eda de los tratamientos contra el c\u00e1ncer: gu\u00eda pr\u00e1ctica","author":"Sibaud","year":"2015"},{"key":"10.1016\/j.ad.2019.01.011_bib0485","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: A useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0490","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2019hand-foot\u2019) syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0495","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0001-7310(08)74677-5","article-title":"Chemotherapy-induced acral erythema: A clinical and histopathologic study of 44 cases","volume":"99","author":"Hueso","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2019.01.011_bib0500","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jaad.2011.09.031","article-title":"Chemotherapy-induced acral erythema sparing the palms","volume":"67","author":"Housholder","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0505","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0510","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/15569527.2010.498397","article-title":"Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas","volume":"29","author":"Ferreira","year":"2010","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.ad.2019.01.011_bib0515","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/86.7.557","article-title":"Prevention of docetaxel-induced erythrodysesthesia with local hypothermia","volume":"86","author":"Zimmerman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ad.2019.01.011_bib0520","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/85.17.1432","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere","volume":"85","author":"Vukelja","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ad.2019.01.011_bib0525","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0190-9622(98)70361-5","article-title":"Persistent supravenous erythematous eruption: A rare local complication of intravenous 5-fluorouracil therapy","volume":"39","author":"Pujol","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0530","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1600-0560.1991.tb01547.x","article-title":"Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine","volume":"18","author":"Arias","year":"1991","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ad.2019.01.011_bib0535","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1365-2133.2000.03432.x","article-title":"Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel","volume":"142","author":"Chu","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0540","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","author":"Burris","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2019.01.011_bib0545","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jaad.2014.03.049","article-title":"Acute rash on sun-exposed area during chemotherapy","volume":"71","author":"Alcal\u00e1 Garc\u00eda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0550","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0959-8049(96)00461-3","article-title":"Radiation-recall dermatitis with docetaxel: Establishment of a requisite radiation threshold","volume":"33","author":"Yeo","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2019.01.011_bib0555","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1684\/ejd.2016.2763","article-title":"Scleroderma-like skin changes occurring after the use of paclitaxel without any chemical solvents: A first case report","volume":"26","author":"Shibao","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0560","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ijd.12437","article-title":"Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis","volume":"55","author":"Winkelmann","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0565","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0001-7310(04)76805-2","article-title":"Paclitaxel-induced skin fibrosis of the lower limbs","volume":"95","author":"Escutia","year":"2004","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2019.01.011_bib0570","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2230.2004.01519.x","article-title":"Scleroderma and the taxanes. Is there really a link?","volume":"29","author":"Farrant","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0575","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2012.43.2872","article-title":"Bleomycin-induced Raynaud's phenomenon after single-dose exposure: Risk factors and treatment with intravenous iloprost infusion","volume":"31","author":"McGrath","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0580","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.1989.7.7.940","article-title":"Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold","volume":"7","author":"Hansen","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0585","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2010.04.021","article-title":"Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: Reappraisal of epidemiological, clinical, and pathological features","volume":"64","author":"Martorell-Calatayud","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0590","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaad.2005.12.011","article-title":"Imatinib-induced eccrine squamous syringometaplasia","volume":"55","author":"Van de Voorde","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0595","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1468-3083.2006.02123.x","article-title":"Eccrine squamous syringometaplasia associated with sunitinib therapy","volume":"21","author":"Sheen","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2019.01.011_bib0600","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/j.jaad.2012.02.038","article-title":"Eccrine squamous syringometaplasia associated with vemurafenib therapy","volume":"67","author":"Story","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0605","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.jaad.2013.06.049","article-title":"Eccrine squamous syringometaplasia associated with dabrafenib therapy","volume":"69","author":"Liuti","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0610","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1365-2230.2001.00785.x","article-title":"Neutrophilic eccrine hidradenitis in two neutropaenic patients","volume":"26","author":"Keane","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0615","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/bjd.15259","article-title":"Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: A new cutaneous adverse event","volume":"176","author":"Herms","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0620","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/bjd.15582","article-title":"Neutrophilic eccrine hidradenitis can be induced by BRAF inhibitors","volume":"176","author":"Basu","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0625","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2011.02.026","article-title":"Chemotherapy-induced alopecia","volume":"67","author":"Chon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0630","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000102031","article-title":"Hair loss pattern due to chemotherapy-induced anagen effluvium: A cross-sectional observation","volume":"215","author":"Yun","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2019.01.011_bib0635","first-page":"147","article-title":"Hair and cancer chemotherapy: Consequences and nursing care--a literature study","volume":"10","author":"Batchelor","year":"2001","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ad.2019.01.011_bib0640","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00001622-200203000-00012","article-title":"Cutaneous toxicities of cancer therapy","volume":"14","author":"Alley","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0560.1993.tb01242.x","article-title":"The cutaneous histopathology of chemotherapeutic reactions","volume":"20","author":"Fitzpatrick","year":"1993","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ad.2019.01.011_bib0650","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","article-title":"Permanent chemotherapy-induced alopecia: Case report and review of the literature","volume":"63","author":"Tallon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0655","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1440-0960.2000.00405.x","article-title":"Permanent alopecia following chemotherapy and bone marrow transplantation","volume":"41","author":"Tran","year":"2000","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0660","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2353\/ajpath.2006.050163","article-title":"P75 neurotrophin receptor-mediated signaling promotes human hair follicle regression (Catagen)","volume":"168","author":"Peters","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ad.2019.01.011_bib0665","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2133.2009.09043.x","article-title":"Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer","volume":"160","author":"Prevezas","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0670","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.2830480305","article-title":"Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis","volume":"48","author":"Tornebohm-Roche","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ad.2019.01.011_bib0675","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM196911132812004","article-title":"Folliculitis induced by actinomycin D","volume":"281","author":"Epstein","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2019.01.011_bib0680","first-page":"469","article-title":"Folliculitis induced by actinomycin D","volume":"72","author":"Henkes","year":"1981","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2019.01.011_bib0685","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0690","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.coc.0000026486.56886.18","article-title":"Cutaneous hand and foot toxicity associated with cancer chemotherapy","volume":"26","author":"Childress","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0695","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.det.2007.08.006","article-title":"Cutaneous reactions to chemotherapy: Commonly seen, less described, little understood","volume":"26","author":"Sanborn","year":"2008","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ad.2019.01.011_bib0700","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(01)06650-8","article-title":"Clinical picture: Leopard-like vitiligo with capecitabine","volume":"358","author":"Schmid-Wendtner","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2019.01.011_bib0705","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12029-009-9068-9","article-title":"Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer","volume":"39","author":"Vickers","year":"2008","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ad.2019.01.011_bib0710","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annder.2012.12.012","article-title":"Pigmentary disorders induced by anticancer agents. Part I: Chemotherapy","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2019.01.011_bib0715","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mjd.2002.104509","article-title":"Generalized hyperpigmentation with daunorubicin chemotherapy","volume":"46","author":"Kroumpouzos","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0720","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/00007611-197912000-00040","article-title":"Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy","volume":"72","author":"Krutchik","year":"1979","journal-title":"South Med J"},{"key":"10.1016\/j.ad.2019.01.011_bib0725","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13555-015-0085-2","article-title":"Trastuzumab-associated flagellate erythema: Report in a woman with metastatic breast cancer and review of antineoplastic therapy-induced flagellate dermatoses","volume":"5","author":"Cohen","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2019.01.011_bib0730","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/SMJ.0b013e3181ce0f5e","article-title":"Antineoplastic agent-associated serpentine supravenous hyperpigmentation: Superficial venous system hyperpigmentation following intravenous chemotherapy","volume":"103","author":"Geddes","year":"2010","journal-title":"South Med J"},{"key":"10.1016\/j.ad.2019.01.011_bib0735","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4103\/0378-6323.156191","article-title":"Serpentine supravenous hyperpigmentation induced by docetaxel","volume":"81","author":"Das","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2019.01.011_bib0740","doi-asserted-by":"crossref","first-page":"390","DOI":"10.12998\/wjcc.v4.i12.390","article-title":"Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation","volume":"4","author":"Cohen","year":"2016","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ad.2019.01.011_bib0745","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1525-1470.2007.00359.x","article-title":"Eruptive post-chemotherapy in situ melanomas and dysplastic nevi","volume":"24","author":"Reutter","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2019.01.011_bib0750","doi-asserted-by":"crossref","first-page":"vii167","DOI":"10.1093\/annonc\/mds294","article-title":"Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines","volume":"23","author":"P\u00e9rez Fidalgo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2019.01.011_bib0755","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.soncn.2010.11.010","article-title":"Extravasation management: Clinical update","volume":"27","author":"Schulmeister","year":"2011","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ad.2019.01.011_bib0760","unstructured":"National Cancer Institute. Common terminology Criteria for Adverse Events (CTCAE) [consultado 19 Nov 2017]. Disponible en: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"10.1016\/j.ad.2019.01.011_bib0765","first-page":"106","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ad.2019.01.011_bib0770","unstructured":"WHODrug portfolio [consultado 14 Dic 2017]. Dsiponible en: https:\/\/www.who-umc.org\/whodrug\/whodrug-portfolio"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019301127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019301127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:31:33Z","timestamp":1762075893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731019301127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0001731019301127"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2019.01.011","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manejo cl\u00ednico de los eventos adversos cut\u00e1neos en pacientes tratados con quimioterapia: consenso nacional de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda y de la Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2019.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}